论文部分内容阅读
[目的]观察含卡培他滨方案治疗16例晚期消化道癌的疗效和毒副作用。[方法]卡培他滨剂量为每天2500mg/m2,分两次口服 ,连服14天 ;部分联合草酸铂 ,剂量为130mg/m2,d1,均3周为1个周期。[结果]14例有可观察病灶 ,均以CT检查结果作为测量病灶大小的依据 ,并以此评定治疗效果。总有效率 (CR +PR)为49.99% ;完全缓解 (CR)2例 (14.28% ) ,部分缓解 (PR)5例 (35.71 % ) ;病情稳定 (SD)6例(42.85%) ;病情进展1例(7.14 % )。临床获益患者 (CR +PR +SD)92.86%。主要不良反应为手足综合征37.50 % (6/16) ,3例Ⅲ度(18.75%) ,其余较轻 ;Ⅰ～Ⅱ度腹泻18.75% (3/16) ,1例十二指肠球部溃疡穿孔。Ⅰ～Ⅱ度贫血和白细胞下降18.75% (3/16)。[结论]含卡培他滨化疗方案治疗晚期消化道癌有较高的缓解率 ,较报道的单药治疗效果明显。副作用有手足综合征、轻度腹泻、轻度贫血和白细胞下降。对既往有消化道溃疡病史的患者使用时应特别慎重。
[Objective] To observe the curative effect and toxicity of capecitabine in 16 patients with advanced gastrointestinal cancer. [Method] The dose of capecitabine was 2500mg / m2 every day. Oral administration was given twice daily for 14 days. Some of the oxaliplatin combined with oxaliplatin at a dose of 130mg / m2 and d1 were given one cycle for three weeks. [Results] Fourteen cases had observable lesions, all based on the CT examination results as the basis for measuring the size of the lesion, and to evaluate the therapeutic effect. The total effective rate (CR + PR) was 49.99%; 2 cases (14.28%) of complete remission (CR), 5 cases (35.71%) of partial remission (PR); 6 cases (42.85%) of stable disease 1 case (7.14%). Clinical benefit patients (CR + PR + SD) 92.86%. The main adverse reactions were hand-foot syndrome (37.50%), 3 cases (3.75%), the others were mild; the second-degree diarrhea was 18.75% (3/16), and the second case was duodenal ulcer perforation. Ⅰ ~ Ⅱ degree anemia and leukopenia 18.75% (3/16). [Conclusion] The curative effect of capecitabine chemotherapy in patients with advanced digestive tract cancer is higher than that reported in single drug treatment. Side effects are hand-foot syndrome, mild diarrhea, mild anemia and leukopenia. The history of patients with previous history of peptic ulcer should be used with particular caution.